Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176917 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplantation for Hurler
A Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00176917: Completed Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00176917 is a Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 41 participants, below the 62-participant average among 6 other Mucopolysaccharidosis VI trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00176917, a Phase 2 study of Mucopolysaccharidosis VI and Mucopolysaccharidosis I, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease.
Primary Outcome
Donor-derived engraftment determined by restriction fragment length polymorphism (RFLP).
Conditions Studied
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG Busulfan, Cyclophosphamide, ATG
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 1999-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00176917 record still lists
NCT00176917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 62-participant average among 6 other Mucopolysaccharidosis VI trials with a reported enrollment target (34% lower).
The record links to 4 conditions, with Mucopolysaccharidosis VI appearing as the primary indexed condition, and to 2 interventions - of which Stem Cell Transplant is the first listed.
NCT00176917 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00176917 about?
NCT00176917 is a clinical study titled "Stem Cell Transplantation for Hurler". The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease.
What is the current status of trial NCT00176917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 1999-05. Estimated completion is 2010-05.
What conditions does trial NCT00176917 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis VI, Mucopolysaccharidosis I, Mannosidosis, Mucolipidosis Type II (I-cell Disease).
What interventions are being tested in trial NCT00176917?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), Busulfan, Cyclophosphamide, ATG (DRUG).
Who is sponsoring clinical trial NCT00176917?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00176917 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucopolysaccharidosis VI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry of Patients Diagnosed With Lysosomal Storage Diseases
RECRUITING
-
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
ACTIVE NOT RECRUITING · Phase 1
-
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
COMPLETED
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Study of rhASB in Patients With Mucopolysaccharidosis VI
COMPLETED · Phase 3
-
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia